| Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. | |
| | |
MedLine Citation:
|
PMID: 18996784 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine the prevalence of valvular heart disease in a cohort of patients taking cabergoline for the management of hyperprolactinemia. METHODS: A retrospective review of medical records identified patients with hyperprolactinemia who underwent evaluation at Vanderbilt University Medical Center between January and June 2007. The medical records of those patients who were prescribed cabergoline and who underwent elective echocardiography were reviewed for details pertaining to cardiac valvular abnormalities and cabergoline use. RESULTS: Forty-five patients (mean age, 41 +/- 10 years [SD]) taking 0.91 +/- 0.96 mg of cabergoline per week for a mean duration of 39 +/- 29 months underwent echocardiography. Abnormalities of the cardiac valves were present in 3 patients (7%): 1 patient exhibited mild mitral regurgitation, 1 patient had focal aortic valve thickening, and 1 patient demonstrated mitral valve thickening. We found no significant difference in either the cumulative dose of cabergoline (P = .800) or the duration of cabergoline therapy (P = .745) between those patients with and those without these echocardiographic abnormalities. CONCLUSION: We found echocardiographic valve abnormalities in 3 of 45 patients (7%) who had been prescribed cabergoline for the management of hyperprolactinemia. This prevalence of valvular heart disease after approximately 3 years of cabergoline treatment is no different from that previously reported in normal populations as determined by echocardiography. |
| | |
Authors:
|
Jessica K Devin; Vipul T Lakhani; Benjamin F Byrd; Lewis S Blevins |
Related Documents
:
|
14559124 - Eighteen-year experience with echinococcosus of the heart: clinical and echocardiograph... 580794 - Neurologic complications of bacterial endocarditis. 7369664 - Have you checked all your breast implants? 3510084 - Comparative accuracy of two-dimensional echocardiography and doppler pressure half-time... 6720684 - Pancytopenia with hypercellular bone marrow--a possible paraneoplastic syndrome in carc... 9605054 - Mechanical dysfunction of the left atrium and the left atrial appendage following cardi... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists Volume: 14 ISSN: 1934-2403 ISO Abbreviation: Endocr Pract Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-11-10 Completed Date: 2009-04-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9607439 Medline TA: Endocr Pract Country: United States |
Other Details:
|
Languages: eng Pagination: 672-7 Citation Subset: IM |
Affiliation:
|
Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. jkdevin@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Cohort Studies Echocardiography Ergolines / adverse effects*, therapeutic use* Female Heart Valve Diseases / chemically induced* Humans Hyperprolactinemia / drug therapy* Male Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Ergolines; 81409-90-7/cabergoline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence of osteoporosis in ambulatory postmenopausal women from a semiurban region in Southern In...
Next Document: Influence of lower cutoff values for 100-g oral glucose tolerance test and glycemic profile for iden...